Abstract 363P
Background
Oral cancer is distressing cancer that affects physically and emotionally and is associated with an adverse impact on mental well-being and financial distress. Informal caregivers are a significant source of support to the patient during and after the treatment of cancer patients. Caregiving may become a burden leading to poor quality of life among caregivers. The study intends to evaluate the effect of a patient's financial distress and psychological well-being on the caregiver's health-related quality of life in early vs advanced oral cancer.
Methods
All oral cancer patients treated with curative intent at our institute from September 2019 to March 2022, with a minimum of 6 months follow-up and disease-free, were included in this study, along with the informal caregivers of the patients. Caretakers not suffering from chronically ill and incurable diseases are included in the study. Patients and caregivers were categorised into early-stage (Group A) and advanced-stage (Group B) based on the clinical staging of patients with oral cancer. The patient's financial distress was evaluated using the COST FACIT questionnaire, and Psychological well-being using DASS 21 questionnaire. The quality of life of the caregivers was evaluated using the WHOQOL BREF questionnaire.
Results
A total of 79 patients and their caregivers were included. The median age is 49 among patients and 38 among caregivers. Twenty-one were in Group A; the rest, fifty-eight, were in Group B. It was observed that the patient in group B has Significant financial distress (p<0.05). There was no difference in HRQOL among caregivers of both groups. There was no correlation between financial distress scores and the caregiver's QOL. There was no effect of the patient's psychological well-being on the QOL of caregivers in group A. However, patients with depression in group B had a significant impact on the caregivers' QOL in the psychological (p <0.05) and environmental domains (p <0.05).
Conclusions
The lack of psychological well-being of patients with advanced-stage cancer significantly influences informal caregivers' psychological and environmental quality of life domains.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract